Overview

Inhaled Selective Pulmonary Vasodilators for Advanced Heart Failure Therapies and Lung Transplantation Outcomes

Status:
Active, not recruiting

Trial end date:
2021-10-05

Target enrollment:

Participant gender:

Summary

1. to conduct a clinical investigation to determine if inhaled epoprostenol (Veletri®, iEPO) and inhaled nitric oxide (iNO) will have similar impact on outcomes in adult patients undergoing durable LVAD placement, heart transplantation, or lung transplantation 2. to conduct a cost-capture analysis on the expense each drug incurs per patient.

Phase:

Phase 4

Details

Lead Sponsor:

Duke University

Treatments:

Nitric Oxide
Vasodilator Agents